Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in Pediatric PAH
NCT01332331Phase 2Terminated
- Sponsor
- GSK
- Start
- Jan 2011
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by GSK. Started Jan 2011; status: terminated.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01332331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01332331.